Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of dolutegravir plus lamivudine in treatment-naive HIV infection
ChiCTR1900027640Phase 4Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir and lamivudine in human immunodeficiency virus infection (HIV), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Virological breakthrough rate and CD4+ T lymphocyte count. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR1900027640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027640.